Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000971 · ClinicalTrials.gov registry record · Phase 1

The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS

A Phase 1 study, sponsored by Abbott.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target

NCT00000971 is a Phase 1 study that has completed, run by Abbott. The registered enrollment target is 24 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000971, a Phase 1 study, has completed, sponsored by Abbott.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target

Study Summary

To evaluate three doses of clarithromycin in children with AIDS and Mycobacterium avium complex (MAC) infection who are receiving concurrent antiretroviral therapy. Before more extensive evaluation of this promising drug for treatment of MAC infection in children can be done, it is important to study the pharmacokinetics of this drug in this population, to get information regarding its use in pediatric patients receiving currently available antiretroviral drugs, and to get information on the antimycobacterial activity of this drug.

Interventions

  • DRUG Zidovudine
  • DRUG Clarithromycin
  • DRUG Didanosine

Trial Details

FieldValue
Enrollment Target 24 participants
Phase Phase 1

Sponsor

Abbott

181 total trials

What the Registry Record Tells You About NCT00000971

The ClinicalTrials.gov registry entry for NCT00000971 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Zidovudine is the first listed.

NCT00000971 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00000971 about?

NCT00000971 is a clinical study titled "The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS". To evaluate three doses of clarithromycin in children with AIDS and Mycobacterium avium complex (MAC) infection who are receiving concurrent antiretroviral therapy. Before more extensive evaluation of this promising drug for treatment of MAC infection in children can be done, it is important to stu...

What is the current status of trial NCT00000971?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants.

What interventions are being tested in trial NCT00000971?

The interventions under investigation include: Zidovudine (DRUG), Clarithromycin (DRUG), Didanosine (DRUG).

Who is sponsoring clinical trial NCT00000971?

This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.